RecruitingPlaque PsoriasisMetabolic Dysfunction-Associated Steatotic Liver Disease
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Eligible age
18–100 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis \[PsA\]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine clinical practice in Spain, as well as hepatic biomarker trajectories. The study will use electronic medical record (EMR) data from multiple Spanish hospitals.
Sponsor: Novartis Pharmaceuticals
You may qualify if…
- ✓ Patients with a first recorded secukinumab prescription between 01 January 2021 and 31 December 2023.
- ✓ Patients aged ≥18 years at index date.
- ✓ Patients with no prior secukinumab exposure in available EMR history.
- ✓ Secukinumab must be patient's first-, second-, or third-line biologic therapy for psoriasis/psoriatic arthritis (PsA).
- ✓ Patients with documented administration per Summary of Product Characteristics dosing recommendations (SmPC).
- ✓ Patients with confirmed plaque psoriasis with or without PsA.
- ✓ Patients with at least one cardiometabolic risk factor.
- ✓ Patients with a confirmed MASLD diagnosis.
You may not qualify if…
- ✕ Patients with evidence of MASLD absence.
- ✕ Patients with malignant liver disease.
- ✕ Patients with a history of liver transplantation.
- ✕ Patients with alcohol use disorder.
- ✕ Patients with other chronic liver diseases.
- ✕ Patients with diseases or treatments which cause thrombocytopenia.
- ✕ Patients with decompensated cirrhosis.
- ✕ Other protocol-defined inclusion/exclusion criteria may apply.
Source: ClinicalTrials.gov · NCT07683065 · last updated 2026-08-14